Self-replicating RNA (srRNA) therapeutics and vaccines
Replicate Bioscience is a San Diego biotech founded in 2020 by RNA-vaccine veterans Nathaniel Wang (CEO) and Andrew Geall to build self-replicating RNA (srRNA) medicines designed to be more durable, tolerable and lower-dose than conventional mRNA. It raised a $40M Series A from Apple Tree Partners in 2021 and has partnered with Novo Nordisk to develop srRNA therapies for obesity and diabetes.
Biotech📍 San Diego, CAFounded 2020
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Replicate Bioscience going public?
No. Replicate Bioscience is private and has not filed to go public. There is no S-1 on file.
What is Replicate Bioscience's valuation in 2026?
No confirmed valuation is on record for Replicate Bioscience. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Replicate Bioscience filed an S-1?
No public S-1 is on file for Replicate Bioscience.
Who are Replicate Bioscience's investors?
Replicate Bioscience's investors include Apple Tree Partners (ATP).
How much has Replicate Bioscience raised?
Replicate Bioscience has raised $40M in total across 1 disclosed round, most recently a Series A of $40M in Jan 2021.
Is Replicate Bioscience publicly traded — can you buy Replicate Bioscience stock?
No. Replicate Bioscience is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Replicate Bioscience on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Series A — $40M (Jan 2021) · Lead: Apple Tree Partners
IPO Status
private
Fundraising Status
Series A · $40M · 5y 8mo ago
privateTotal raised $40M1 disclosed rounds
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Series A
$40M
Jan 2021
Apple Tree Partners
—
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
1
0 active · 0 recruiting
Lead phase
Phase 1
most advanced registered study
Focus areas
Healthy Volunteers
Latest trial start
2023-09-01
Name-verified against lead sponsor "Replicate Bioscience" on ClinicalTrials.gov as of 2026-09-27. Verify on ClinicalTrials.gov ↗
Talent Signal
No public careers page or job board could be found for Replicate Bioscience as of 2026-09-14. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
Founders & Key People
Nathaniel WangAndrew Geall
Investors
Apple Tree Partners (ATP)
Products
Self-replicating RNA (srRNA) platform
srRNA vaccines and therapeutics
Competitors
Arcturus Therapeutics · Gritstone bio · Therna Biosciences
BiotechRNA TherapeuticsSelf-amplifying RNATechBio
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.